Sight Sciences (SGHT)
NASDAQ:SGHT
Want to see SGHT full AI Analyst Report?
SGHT Stock Chart & Stats
$4.09
-$0.06(-1.81%)
At close: 4:00 PM EST
$4.09
-$0.06(-1.81%)
Day’s Range― - ―
52-Week Range$3.11 - $9.24
Previous CloseN/A
Volume59.09K
Average Volume (3M)150.61K
Market Cap
$287.28M
Enterprise Value$229.39M
Total Cash (Recent Filing)$84.96M
Total Debt (Recent Filing)$41.76M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding54,409,943
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$8.54Price Target Upside108.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$84.48M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~86% gross margins reflect strong product-level economics and favorable unit economics from capital systems plus consumables. Durable high margins provide structural operating leverage as revenue scales, supporting reinvestment in commercial expansion and reducing reliance on external financing over time.
Revenue Rebound And Raised GuidanceReturn to double-digit revenue growth and an upwardly revised full-year outlook signal improving demand and validated commercial execution in core interventional glaucoma and nascent dry-eye. Durable top-line momentum supports the company's stated path to cash-flow breakeven and reduces medium-term funding dependency.
Early Dry‑eye Traction & Cross‑sellRapid SmartLids adoption and cross-sells into existing glaucoma accounts show a scalable go-to-market and product adjacency. The consumable-heavy TearCare model can drive recurring revenue per account, creating durable lifetime value if payer coverage and national penetration continue to expand.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow forces continued reliance on balance-sheet resources or external financing. Even with improved quarterly burn, sustained cash deficits erode capital over time, limit strategic flexibility, and raise dilution or refinancing risk until profitable operations are achieved.
Ongoing Net LossesDespite strong gross margins, the company remains unprofitable, indicating operating expenses and scale gaps persist. Continued losses undermine returns on equity, restrict self-funded growth, and mean that achieving durable profitability requires sustained revenue scale or further structural cost reductions.
Legal Judgment Realization RiskA favorable patent award could materially extend runway via damages and royalties, yet appeals and parallel reexaminations create timing and realization uncertainty. Relying on contingent legal proceeds for financial stability is structurally risky for planning and capital allocation decisions.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.11 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $287.28M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on May 06, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.066.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.15.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 54,409,943 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went up 23.023%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.54 (108.74% Upside)
$8.54 (108.74% Upside)
Hedge Fund Trend
Increased
By 29.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $308.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
-59.10%
Trailing 12-Months
Asset Growth
-15.41%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
SGHT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: the company returned to double‑digit revenue growth, raised 2026 revenue guidance, showed meaningful early traction in the newly reimbursed Interventional Dry Eye market, sustained very strong gross margins, and demonstrated improved cash usage and lower adjusted operating expenses. Challenges remain—most notably continued net losses, concentrated payer coverage for TearCare, early penetration of the dry eye opportunity, and uncertainty around timing of cash from the legal judgment—but these risks were framed as manageable and addressable with targeted commercial investment. On balance the positive progress, guidance raise, margin strength, and improving cash dynamics outweigh the outstanding risks.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$8.54
▲(108.74% Upside)
Technical Analysis
Ownership Overview
33.79% Insiders
5.89% Mutual Funds
13.91% Other Institutional Investors
39.38% Public Companies and
Individual Investors